

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/650,591	08/27/2003	Noubar B. Afeyan	COTH-P02-001	COTH-P02-001 7918	
28120	7590 08/09/2005		EXAMINER		
	AVE IP GROUP	MEAH, MOHAMMAD Y			
ROPES & GR ONE INTERN	RAY LLP NATIONAL PLACE		ART UNIT PAPER NUMBER 1652		
BOSTON, M	A 02110-2624				
			DATE MAILED: 09/00/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Applic	ation No.	Applicant(s)	· ·			
Office Action Summary		0,591	AFEYAN ET AL.				
		ner	Art Unit				
	Mohar	nmad Meah	1652				
The MAILING DATE of this con Period for Reply	nmunication appears on	the cover sheet with the c	correspondence add	iress			
A SHORTENED STATUTORY PERIOD THE MAILING DATE OF THIS COM  - Extensions of time may be available under the proafter SIX (6) MONTHS from the mailing date of thi  - If the period for reply specified above is less than  - If NO period for reply is specified above, the maxi  - Failure to reply within the set or extended period for any reply received by the Office later than three mearned patent term adjustment. See 37 CFR 1.70	MUNICATION.  wisions of 37 CFR 1.136(a). In n s communication.  thirty (30) days, a reply within the mum statutory period will apply a or reply will, by statute, cause the tonths after the mailing date of th	o event, however, may a reply be tir statutory minimum of thirty (30) day nd will expire SIX (6) MONTHS from application to become ABANDONE	nely filed rs will be considered timely the mailing date of this co ED (35 U.S.C. § 133).				
Status							
1) Responsive to communication	s) filed on <u>02 July 2005</u>	j.					
2a) ☐ This action is <b>FINAL</b> .	2b)⊠ This action	is non-final.					
• •	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) Claim(s) 1-41 is/are pending in 4a) Of the above claim(s)  5) Claim(s) is/are allowed.  6) Claim(s) is/are rejected.  7) Claim(s) is/are objected.  8) Claim(s) 1-41 are subject to re	_ is/are withdrawn from						
Application Papers							
9) The specification is objected to	by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) inc	•	·					
Priority under 35 U.S.C. § 119							
a) Acknowledgment is made of a case a) All b) Some * c) None 1. Certified copies of the property of the property of the property of the certified copies of the property of the certified copies of the certified copi	of: iority documents have iority documents have opies of the priority doc rnational Bureau (PCT	been received. been received in Applicat uments have been receiv Rule 17.2(a)).	ion No ed in this National	Stage			
Attachment(s)	•						
1) Notice of References Cited (PTO-892)		4) Interview Summary					
Notice of Draftsperson's Patent Drawing Re     Information Disclosure Statement(s) (PTO-1     Paper No(s)/Mail Date		Paper No(s)/Mail D 5) Notice of Informal I 6) Other:		)-152)			

## **DETAILED ACTION**

Claims 1-41 in this application are pending.

## Election/Restrictions

Inventions in claims 1-41 comprise adzymes (a fusion protein comprising protease domains and targeting domains (comprising antibody and / or polypeptide) attached via no linker or linker). Wherein the protease is selected from any protease (claims 1, 41) or zymogen (claim 3) or serine proteinase and metalloproteinase (claim 4). Protease includes a wide variety of different protease enzymes as listed in pages 85-90 of specification. Serine proteinase and metalloproteinase also include a wide variety of different enzymes as stated in page 35-36. Targeting moiety is selected from any class of a wide variety of species of polypeptide, polypeptide complex, antibody, Fab. scFv, artificial protein, etc. Each catalytic domain of the fusion proteins encompassed by the instant claims is a patentably distinct protein having a different structure than the other catalytic domains encompassed by the instant claims. Similarly, each specific targeting domain fusion encompassed by the instant claims is a patentably distinct protein having a different structure than the other targeting domains encompassed by the instant claims. Each specific linker encompassed by the instant claims is a patentably distinct amino acid sequence having a different structure than the other linkers encompassed by the instant claims. N combinations of catalytic domain with N combinations of targeting domain will produce  $N^2$  (such as 10 X10 = 100) patentably distinct adzymes having different structures. Furthermore each specific fusion protein will have distinct functional properties as well. As such each adzyme

Art Unit: 1652

fusion protein is an independent invention. In view of the enormous number of independent inventions encompassed the examiner has not attempted to exhaustively list each independent invention herein. Applicants are required to identify a specific adzyme fusion protein for examination by electing a specific protease or proteinase and a specific targeting domain. Applicants are further required to identify which claims encompass the elected invention.

Page 3

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 1652

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD

Examiner, Art Unit 1652

Recombinant Enzymes, 3C31 Remsen Bld 400 Dulany Street, Alexandria, VA 22314

Telephone: 517-272-1261

REBECCA E. PRUUTY
PRIMARY EXAMINER

SAOUP 1800